• Tiamulin Metabolites Across Farm Animal Species

  2026-08-16

  This study mapped Tiamulin biotransformation across rats, chickens, swine, goats, and cows using in vitro and in vivo experiments coupled with UHPLC–quadrupole/time-of-flight mass spectrometry. Its main contribution is the identification of 26 metabolites, revealing species-dependent phase I pathways and refining candidate marker residues for residue monitoring in pigs and chickens.

• PGF2α/PTGFR Control of Endometrial Breakdown

  2026-08-15

  This 2024 mouse menstrual-like model study identifies PGF2α/PTGFR as a HIF-1α-regulated pathway connecting endometrial shedding with vascular remodeling. Pharmacologic inhibition with AL-8810 reduced tissue breakdown, VEGF-A expression, and vascular permeability, providing a receptor-level framework for studying prostaglandin F2α signaling in menstruation.

• Ginsenoside Rg1: Neuroimmune Protection After Anesthesia

  2026-08-15

  The reference study shows that Ginsenoside Rg1 counteracts prolonged isoflurane anesthesia-associated behavioral, synaptic, inflammatory, and intestinal barrier abnormalities in mice. Its key mechanistic contribution is evidence that regulatory T cells are required for restoring gut–immune–brain axis function, although translation beyond this controlled preclinical model remains uncertain.

• MTT Assays for Hemodynamics-Informed Nanomedicine

  2026-08-14

  MTT provides a practical metabolic activity measurement for evaluating how thrombus-targeting nanomedicines affect cultured cells. This guide connects MTT assay design with arterial-versus-venous hemodynamics while clarifying what the readout can—and cannot—prove.

• Cy3 TSA Fluorescence System Kit: Practical Guide

  2026-08-14

  Learn how Cy3 TSA Fluorescence System Kit, SKU K1051, can strengthen fixed-cell and tissue imaging when conventional fluorescence is insufficient. This scenario-based guide covers assay compatibility, protocol controls, quantitative interpretation, and practical vendor-selection criteria for reliable fluorescence microscopy detection.

• Calpeptin and EV Release in Triple-Negative Breast Cancer

  2026-08-13

  McNamee et al. systematically compared several pharmacological strategies for suppressing extracellular vesicle release from triple-negative breast cancer cells. Their results indicate that multiple EV subpopulations contribute to the transfer of aggressive traits, and that substantial inhibition of total EV release may be necessary to meaningfully reduce effects on recipient-cell migration.

• BKT140 (BL-8040) CXCR4 Research Workflows

  2026-08-13

  BKT140 (BL-8040) connects CXCR4 biology with practical assays for chemotaxis, tumor-cell survival, microenvironmental retention, and hematopoietic stem cell mobilization. This guide emphasizes assay design, formulation control, orthogonal validation, and troubleshooting across lymphoma, leukemia, multiple myeloma, and solid-tumor models.

• Intravesical p21 mRNA-LNP Therapy in Bladder Cancer

  2026-08-12

  A 2026 FASEB Journal study developed lipid nanoparticles carrying chemically modified p21 mRNA for localized intravesical treatment of bladder cancer. The approach restored nuclear p21, suppressed tumor growth in an orthotopic mouse model, and limited systemic exposure, while also highlighting important translational questions about dosing, formulation, and long-term safety.

• Hoechst 33342 for NECSO Cell Death Assays

  2026-08-12

  Use Hoechst 33342 to convert sodium-overload experiments into interpretable nuclear and cell-population readouts. This workflow distinguishes downstream chromatin and morphology changes from the mitochondrial energy failure that defines NECSO, while providing practical guidance for live-cell imaging, cell cycle analysis, and apoptosis-oriented validation.

• AC Electrokinetic HRP Immobilization: Activity and Methods

  2026-08-11

  The reference study quantitatively evaluates horseradish peroxidase activity after AC dielectrophoretic immobilization on titanium nitride nanoelectrode arrays. Using Amplex Red and hydrogen peroxide fluorescence microscopy, the authors report detection down to 60 fg HRP and retain up to 45% of the activity expected for an ideal enzyme monolayer, supporting DEP-based enzyme biosensors while highlighting important limits on activity interpretation.

• Prednisone Beyond Immunosuppression: Translational Strategy

  2026-08-10

  Prednisone is more than a familiar immunosuppressant: it is a controllable probe of lymphocyte state, cytokine signaling, and apoptosis. This thought-leadership guide shows how translational researchers can move from mechanism to reproducible assays, while using exposure discipline and metabolomics-inspired evidence design to strengthen interpretation.

• (-)-Arctigenin: A Mechanistic Assay Roadmap

  2026-08-09

  (-)-Arctigenin offers a chemically defined way to interrogate NF-κB and MEK1 signaling, but its value in breast cancer research depends on separating pathway suppression from extracellular-vesicle biology. This article translates the miR-660/KLHL21 study into a rigorous assay strategy for testing mechanism without overstating evidence.

• AZD1390: Reframing ATM Inhibition for G4 Stress

  2026-08-08

  AZD1390 offers translational researchers a potent ATM kinase inhibitor for connecting DNA double-strand break signaling, replication-associated G-quadruplex stress, and radiation response. By integrating REV1–DHX36 biology with preclinical radiosensitization evidence, this article outlines a disciplined strategy for mechanism-led cancer research without overstating what has been directly validated.

• (5Z)-7-Oxozeaenol TAK1 Inhibitor Workflow

  2026-08-07

  Use (5Z)-7-Oxozeaenol to separate TAK1-dependent inflammatory signaling from broader metabolic-stress responses. This practical workflow combines concentration–time optimization, NF-κB and JNK/p38 MAPK readouts, COX-2 measurements, and a focused strategy for testing TAK1 involvement in the AMPK–SQSTM1/NRF2 feedback loop.

• Merbromin as a Mixed-Type Inhibitor of SARS-CoV-2 3CLpro

  2026-08-07

  This study identifies merbromin as a potent, selective mixed-type inhibitor of the SARS-CoV-2 3-chymotrypsin-like protease (3CLpro), a key enzyme in viral replication. By leveraging high-throughput screening and enzymatic kinetics, the research advances understanding of selective protease targeting and lays a scaffold for rational antiviral inhibitor development.

455 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page